Now that we can predict risk accurately, we need to reconsider screening strategies
The recent completion of the Human Genome Project offered great promise that medical genetics would have a population-based impact on the prevention and treatment of inherited conditions. A common inherited condition, hereditary haemochromatosis, was initially touted as a “poster child” for population genetic screening. Most cases are due to homozygosity for a single mutation of the HFE gene, leading to iron overload. Hereditary haemochromatosis is considered an ideal candidate for population genetic screening as genetic susceptibility is common, testing is inexpensive, and iron studies can detect early stages of the disease.1 Most importantly, venesection is a simple and effective way to both prevent and manage the potential sequelae of iron overload,2 which include severe fatigue, arthritis, impotence, cirrhosis, diabetes, and cardiomyopathy.3 However, even for an inherited condition as apparently straightforward as haemochromatosis, justifying population genetic screening has proven more complicated than initially expected.4
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1 Murdoch Childrens Research Institute, Royal Children’s Hospital, Melbourne, VIC.
- 2 University of Melbourne Department of Paediatrics, Royal Children’s Hospital, Melbourne, VIC.
- 1. Allen KJ, Williamson R. Should we genetically test everyone for haemochromatosis? J Med Ethics 1999; 25: 209-214.
- 2. Niederau C, Fischer R, Purschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107-1119.
- 3. Adams PC, Barton JC. Haemochromatosis. Lancet 2007; 370: 1855-1860.
- 4. Gertig DM, Hopper JL, Allen KJ. Population genetic screening for hereditary haemochromatosis [editorial]. Med J Aust 2003; 179: 517-518. <MJA full text>
- 5. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
- 6. Pietrangelo A. Hereditary hemochromatosis. Annu Rev Nutr 2006; 26: 251-270.
- 7. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 1769-1778.
- 8. Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G→ A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211-218.
- 9. Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718-724.
- 10. Andersen RV, Tybjaerg-Hansen A, Appleyard M, et al. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004; 103: 2914-2919.
- 11. Allen KJ, Gurrin LC, Osborne NJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 221-230.
- 12. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001; 33: 1321-1328.
- 13. Whitlock EP, Garlitz BA, Harris EL, et al. Screening for hereditary hemochromatosis: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2006; 145: 209-223.
- 14. Burke W, Thomson E, Khoury MJ, et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA 1998; 280: 172-178.
- 15. Delatycki MB, Allen KJ, Nisselle AE, et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 2005; 366: 314-316.
- 16. Delatycki M, Allen K, Williamson R. Insurance agreement to facilitate genetic testing. Lancet 2002; 359: 1433.